AU720621B2 - Chelating agents and their metal chelates for treating free radicals induced conditions - Google Patents

Chelating agents and their metal chelates for treating free radicals induced conditions Download PDF

Info

Publication number
AU720621B2
AU720621B2 AU32689/97A AU3268997A AU720621B2 AU 720621 B2 AU720621 B2 AU 720621B2 AU 32689/97 A AU32689/97 A AU 32689/97A AU 3268997 A AU3268997 A AU 3268997A AU 720621 B2 AU720621 B2 AU 720621B2
Authority
AU
Australia
Prior art keywords
group
formula
compound
treatment
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU32689/97A
Other languages
English (en)
Other versions
AU3268997A (en
Inventor
Per Jynge
Jan Olof Gustav Karlsson
Robertson Towart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Publication of AU3268997A publication Critical patent/AU3268997A/en
Application granted granted Critical
Publication of AU720621B2 publication Critical patent/AU720621B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Semiconductor Lasers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AU32689/97A 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions Ceased AU720621B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
GB9613182 1996-06-24
PCT/GB1997/001722 WO1997049409A1 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions

Publications (2)

Publication Number Publication Date
AU3268997A AU3268997A (en) 1998-01-14
AU720621B2 true AU720621B2 (en) 2000-06-08

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
AU32689/97A Ceased AU720621B2 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions
AU32688/97A Ceased AU720570B2 (en) 1996-06-24 1997-06-24 Reduction of cardiotoxicity of an antitumor agent using manganese compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU32688/97A Ceased AU720570B2 (en) 1996-06-24 1997-06-24 Reduction of cardiotoxicity of an antitumor agent using manganese compound

Country Status (14)

Country Link
US (2) US6147094A (enExample)
EP (2) EP0936915B1 (enExample)
JP (2) JP4162263B2 (enExample)
CN (2) CN1228703A (enExample)
AT (2) ATE225178T1 (enExample)
AU (2) AU720621B2 (enExample)
BR (1) BR9709942A (enExample)
CA (2) CA2258299A1 (enExample)
DE (2) DE69716104T2 (enExample)
GB (1) GB9613182D0 (enExample)
IL (1) IL127733A0 (enExample)
NO (2) NO985917L (enExample)
NZ (2) NZ333357A (enExample)
WO (2) WO1997049409A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
JP2001527072A (ja) * 1997-12-23 2001-12-25 ニユコメド・イメージング・アクシエセルカペト 一酸化窒素を放出するキレート化剤およびその治療上の使用
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
JP5349722B2 (ja) 1999-10-01 2013-11-20 ディーエムアイ バイオサイエンシズ インコーポレイテッド 金属結合化合物およびその使用方法
FR2823977B1 (fr) * 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
JP4972545B2 (ja) 2004-04-22 2012-07-11 セレーター ファーマスーティカルズ、インク． アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
EP2224925B1 (en) 2007-12-14 2015-09-09 Pledpharma AB Compounds for use in the treatment of cancer
KR101939207B1 (ko) * 2009-07-06 2019-01-16 플레드파르마 에이비 망간 착물 화합물 및 비 망간 착물 형태의 화합물의 조합을 사용하는 약학적 조성물 및 치료 방법
HUE048876T2 (hu) 2011-05-09 2020-08-28 Mayo Found Medical Education & Res Rákos megbetegedések kezelése
BR112014016497B1 (pt) 2012-01-05 2021-02-23 Pledpharma Ab complexos de metal misturados, composição farmacêutica compreendendo os mesmos, métodos de produção e uso
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US20150313921A1 (en) 2012-11-02 2015-11-05 Pledpharma Ab Cancer Treatment Methods
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
CN107073132B (zh) 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
WO2017165440A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
AU2017324947A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
DE69716104T2 (de) 2003-05-28
NZ333315A (en) 2000-07-28
EP0910360A1 (en) 1999-04-28
NO985917L (no) 1999-01-25
IL127733A0 (en) 1999-10-28
CA2258299A1 (en) 1997-12-31
ATE228361T1 (de) 2002-12-15
CA2259150A1 (en) 1997-12-31
ATE225178T1 (de) 2002-10-15
DE69717447T2 (de) 2003-09-11
NZ333357A (en) 2000-08-25
US6258828B1 (en) 2001-07-10
NO985917D0 (no) 1998-12-17
AU720570B2 (en) 2000-06-08
JP2000514044A (ja) 2000-10-24
JP4162263B2 (ja) 2008-10-08
NO985916L (no) 1999-01-25
CN1228694A (zh) 1999-09-15
NO985916D0 (no) 1998-12-17
JP2000513351A (ja) 2000-10-10
US6147094A (en) 2000-11-14
AU3268897A (en) 1998-01-14
BR9709942A (pt) 1999-08-10
DE69716104D1 (de) 2002-11-07
EP0936915A1 (en) 1999-08-25
EP0910360B1 (en) 2002-11-27
WO1997049390A1 (en) 1997-12-31
JP4359651B2 (ja) 2009-11-04
AU3268997A (en) 1998-01-14
CN1228703A (zh) 1999-09-15
WO1997049409A1 (en) 1997-12-31
DE69717447D1 (de) 2003-01-09
GB9613182D0 (en) 1996-08-28
EP0936915B1 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
EP0936915B1 (en) Chelating agents and their metal chelates for treating free radicals induced conditions
EP1060174B1 (en) Nitric oxide releasing chelating agents and their therapeutic use
US5087440A (en) Heterocyclic derivatives of DTPA used for magnetic resonance imaging
EP1054670B1 (en) Use of chelating agents in the treatment of atherosclerotic conditions
US20130157983A1 (en) Compounds for Use in the Treatment of Cancer
AU2010269849B2 (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
EA001870B1 (ru) Способы профилактики и защиты кровеносных сосудов от повреждений (варианты), способы лечения и профилактики различных видов гипертензии, атеросклероза (варианты)
HUP9902838A2 (hu) Kelátképző piridin-származékok és fémkelátjaik alkalmazása szabad gyökök által előidézett állapotok kezelésére alkalmas gyógyszerkészítmények előállítására
Hedlund et al. High molecular weight forms of deferoxamine: novel therapeutic agents for treatment of iron-mediated tissue injury
Mooradian c), United States Patent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired